HIV therapy simulator: A graphical user interface for comparing the effectiveness of novel therapy regimens

Bioinformatics

Volumn 27, Issue 21, 2011, Pages 3065-3066

  Lim, Huat Chye ^a   Curlin, Marcel E ^a   Mittler, John E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE;

ARTICLE; BIOLOGICAL MODEL; COMPUTER GRAPHICS; COMPUTER INTERFACE; COMPUTER PROGRAM; COMPUTER SIMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIROLOGY;

ANTI-HIV AGENTS; COMPUTER GRAPHICS; COMPUTER SIMULATION; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; NEVIRAPINE; SOFTWARE; USER-COMPUTER INTERFACE;

EID: 80054888112     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btr515     Document Type: Article

References (15)

1. Bonhoeffer,S. et al. (1997) Virus dynamics and drug therapy. Proc. Natl Acad. Sci. USA, 94, 6971-6976.
2. Catanzaro,L.M. et al. (2004) Drug interactions with antiretrovirals. Curr. HIV/AIDS, 1, 89-96.
3. Chesney,M. (2000) Factors affecting adherence to antiretroviral therapy. Clin. Infect. Dis., 30 (Suppl. 2), S171-S176.
4. Claxton,A.J. et al. (2001)Asystematic review of the associations between dose regimens and medication compliance. Clin. Ther., 23, 1296-1310.
5. Curlin,M.E. et al. (2007) Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput. Biol., 3, e133.
6. Guay,L.A. et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 354, 795-802.
7. Hosseinipour,M.C. et al. (2009) The public health approach to identify therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first line antiretroviral therapy. AIDS, 23, 1127-1134.
8. Izopet,J. et al. (2002) Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J. Infect. Dis., 185, 1506-1510.
9. Lockman,S. et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med., 356, 135-147.
10. Martinez-Picado,J. et al. (2003) Alternation of antiretroviral drug regimens for HIV infection: a randomized, controlled trial. Ann. Intern. Med., 139, 81-89.
11. Miller,V. et al. (2000a) HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir. Ther., 5, 49-55.
12. Miller,V. et al. (2000b)Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS, 14, 2857-2867.
13. Perelson,A.S. (2002) Modelling viral and immune system dynamics. Nat. Rev. Immunol., 2, 28-36.
14. Ribeiro,R.M. and Bonhoeffer,S. (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl Acad. Sci. USA, 97, 7681-7686.
15. Rong,L. et al. (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med., 2, 30ra32.